Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07148089 | A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | PHASE1 | RECRUITING | 18 | — | — | Feb 23, 2026 | May 1, 2031 | Jun 2, 2026 | 5 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (≥ 18 years of age) | EXPERIMENTAL | Participants will receive a single intravenous (IV) infusion (dose 1) of SGT-501. |
| Cohort 2 (≥ 18 years of age) | EXPERIMENTAL | Participants will receive a single IV infusion (dose 2) of SGT-501. |
| Cohort 3 (≥ 7 to < 18 years) | EXPERIMENTAL | Participants will receive a single IV infusion (level at or below dose(s) assessed in adults) of SGT-501. |
| Name | Type | Description |
|---|---|---|
| SGT-501 | DRUG | IV for infusion |
Inclusion Criteria: Type of Participant and Disease Characteristics: * Clinical diagnosis of CPVT, based on documented history of polymorphic or bidirectional non-sustained ventricular tachycardia with exercise or ventricular ectopy in a pattern consistent with CPVT on EST. * Central Screening lab...